Skip to main content
Clinical Trials/NCT03210558
NCT03210558
Completed
Phase 2

Effects of Moderately Increased Testosterone Concentration on Physical Performance and Behaviour in Healthy Women - a Double-blind, Randomized, Placebo-controlled Study

Karolinska University Hospital1 site in 1 country48 target enrollmentMay 26, 2017

Overview

Phase
Phase 2
Intervention
Placebo cream
Conditions
Athletic Performance
Sponsor
Karolinska University Hospital
Enrollment
48
Locations
1
Primary Endpoint
Aerobic performance
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Trial objectives and purpose: The primary aim is to study the effects of moderately increased testosterone concentration on aerobic performance (endurance running time to exhaustion), and secondary aims to investigate the effects on submaximal work on treadmill, anaerobic capacity, muscle strength, body composition, behaviour and well-being, blood parameters, steroid hormone profile, gynecological parameters and skeletal muscle parameters in young healthy women in a double-blind, randomized, placebo-controlled trial.

Treatment: Ten weeks of transdermal treatment with testosterone cream 10 mg daily or placebo cream in a randomized design (1:1).

Primary outcome: Aerobic performance (running time to exhaustion on treadmill)

Secondary outcomes:

  1. Submaximal work on treadmill (oxygen uptake, ventilation, heart rate, blood lactate and subjective rate of exhaustion)
  2. Anaerobic performance (Wingate test)
  3. Muscle strength (Cybex apparatus, force transducer, counter movement jump)
  4. Body composition (Dual X-ray Absorptiometry: muscle mass, fat mass, bone mass)
  5. Behaviour and well-being (Quality of life, Profile of mood state, Confidence Questionnaire, Aggression Questionnaire)
  6. Blood parameters (hemoglobin, hematocrit, reticulocytes, ferritin, CRP)
  7. Steroid hormone profile in blood and urine
  8. Gynecological evaluation (ovarian and endometrial variables on ultrasound)
  9. Skeletal muscle morphology, metabolic enzymes and muscle protein synthesis

Study population: Fifty healthy menstruating women will be included in the study and randomized to treatment with testosterone or placebo. Inclusion criteria: 18-35 yrs of age; body mass index (BMI) 19-25; non-smoking; a moderate to high self-reported level of recreational physical activity; not taking hormonal contraception and willing to use highly efficient non-hormonal contraception during the study (intrauterine device, bilateral tubal occlusion, vasectomised partner, same-sex partner, or sexual abstinence); accepting to not participate in any sports competitive event during the study period plus one month. Exclusion criteria: the presence of cardiovascular, liver, biliary or renal disease; hyperlipidemia; uncontrolled high blood pressure; endocrinological disorder; oligomenorrhea (menstrual intervals of more than 6 weeks) or amenorrhea (no menstruation for at least 3 months); pregnancy; a history of thromboembolic disorder; any malignancy; and intake of hormonal contraception the last two months prior to the study.

Registry
clinicaltrials.gov
Start Date
May 26, 2017
End Date
June 20, 2018
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Karolinska University Hospital
Responsible Party
Principal Investigator
Principal Investigator

Angelica Lindén Hirschberg

Professor

Karolinska University Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Group B

Placebo cream

Intervention: Placebo cream

Group A

Testosterone cream 1% (Andro-Feme® )

Intervention: Testosterone cream 1% (Andro-Feme® )

Outcomes

Primary Outcomes

Aerobic performance

Time Frame: Baseline and 10 weeks of treatment

Change in endurance exercise time to exhaustion on treadmill

Secondary Outcomes

  • Muscle mass(Baseline and 10 weeks of treatment)
  • Body fat percentage(Baseline and 10 weeks of treatment)
  • Bone mineral density(Baseline and 10 weeks of treatment)
  • Confidence(Baseline and 10 weeks of treatment)
  • Aggression(Baseline and 10 weeks of treatment)
  • Blood parameters(Baseline and 10 weeks of treatment)
  • Physical activity during one week before treatment and one week before the end of treatment(Baseline and 10 weeks of treatment)
  • Submaximal work on treadmill(Baseline and 10 weeks of treatment)
  • Psychological General Well-Being(Baseline and 10 weeks of treatment)
  • Mood(Baseline and 10 weeks of treatment)
  • Anaerobic performance (Wingate test)(Baseline and 10 weeks of treatment)
  • Muscle strength (knee extension torque)(Baseline and 10 weeks of treatment)
  • Functional power development-jump tests(Baseline and 10 weeks of treatment)
  • Steroid hormone profile in blood and urine(Baseline and 10 weeks of treatment)
  • Gynecological evaluation(Baseline and 10 weeks of treatment)
  • Skeletal muscle(Baseline and 10 weeks of treatment)

Study Sites (1)

Loading locations...

Similar Trials